A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemias (CMLs). However, a significant proportion of patients chronically treated with imatinib develop resistance because...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gumireddy, Kiranmai, Baker, Stacey J., Cosenza, Stephen C., John, Premila, Kang, Anthony D., Robell, Kimberly A., Reddy, M. V. Ramana, Reddy, E. Premkumar
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2005
Teme:
Biological Sciences
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC546016/
https://ncbi.nlm.nih.gov/pubmed/15677719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0408283102
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki